Drugs / CRG002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07503028 | Oct 2025 → Jan 2028 expected | type 1 diabetes mellitus | Celregen Therapeutics | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRG-002 | “An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment” NCT07503028 ↗ |
| Modality | Cell therapy | “Allogeneic iPSC-derived Pancreatic Islet Cells” NCT07503028 ↗ |
| Route | Other | “Intraportal infusion or Implantation underneath the abdominal anterior rectus sheat” NCT07503028 ↗ |